About 313 results

ALLMedicine™ Acquired Hemophilia A Center

Research & Reviews  109 results

Acquired Hemophilia A.
Hematology/oncology Clinics of North America; Pai M

Sep 19th, 2021 - Acquired hemophilia A is a potentially severe bleeding disorder caused by antibodies against the patient's own factor VIII. Acquired hemophilia A is rare. It is most commonly diagnosed in older individuals; about one-half of cases of acquired hemo...

Management of acquired hemophilia A: results from the Spanish Registry.
Blood Advances; Mingot-Castellano ME, Pardos-Gea J et. al.

Sep 15th, 2021 - The Spanish Acquired Hemophilia A (AHA) Registry is intended to update the status of AHA in Spain. One hundred and fifty-four patients were included and retrospectively followed-up for a median time of 12 months. Patients were predominantly male (...

Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and...
Journal of Thrombosis and Haemostasis : JTH; Bonnefoy A, Merlen C et. al.

Aug 30th, 2021 - Acquired hemophilia A (AHA) is a potentially life-threatening bleeding disorder caused by factor VIII (FVIII) autoantibodies, involving various immunoglobulin (Ig) isotypes and IgG subclasses. We analyzed the profile of Ig against FVIII in patient...

Feasibility of therapeutic plasma exchange-based combination therapy in the treatment o...
Medicine Wang LY, Shen Y et. al.

Aug 17th, 2021 - Poor availability and a lack of affordability of bypassing agents (recombinant activated factor VII and activated prothrombin complex concentrate) in west China prompted us to investigate an alternative cost-effective combination therapy. We aimed...

see more →

Drugs  5 results see all →

News  11 results

An unusual cause of bruising

Aug 1st, 2019 - FACTOR VIII INHIBITOR EVALUATION 2. What is the most likely underlying condition associated with this patient’s factor VIII inhibitor? Autoimmune disease Malignancy A medication Unknown (idiopathic) Acquired hemophilia A (AHA) is a rare disorder c.

FVIII/W ratio may help predict relapse in hemophilia A
Caleb Rans

May 22nd, 2019 - The FVIII/W (factor VIII:C/von Willebrand factor antigen) ratio appears to be a reliable biological marker to predict recovery and/or relapse in patients with acquired hemophilia A, according to a retrospective analysis. Marc Trossaert, MD, PhD, o.

FXIII replacement may improve hemostasis in acquired hemophilia A
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

CardioBreak: Watchman Registry for CMS $$, U.K. Says No to PCSK9 Drug

Nov 23rd, 2015 - Trends-in-Medicine (access restricted) dug up details on the proposed CMS coverage restrictions for the Watchman left atrial appendage (LAA) closure device, which revealed that: The agency is likely to clarify its requirement that patients not be ...

EC approves drug for acquired hemophilia A
HT Staff

Nov 15th, 2015 - Vial of Obizur Photo courtesy of Baxter International Inc. The European Commission (EC) has approved a recombinant porcine factor VIII (FVIII) product, Obizur, to treat bleeding episodes in adults with acquired hemophilia A caused by autoantibodie.

see more →